Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$44.64 USD

44.64
16,427,322

-0.21 (-0.47%)

Updated Apr 29, 2024 04:00 PM ET

After-Market: $44.65 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..

FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease

The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.

FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE

If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.

Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know

Bristol Myers Squibb (BMY) closed at $59.16 in the latest trading session, marking a +0.44% move from the prior day.

Bristol Myers' (BMY) Opdivo Positive in Late-Stage NSCLC Study

Bristol Myers' (BMY) perioperative regimen of neoadjuvant Opdivo with chemotherapy, followed by surgery and adjuvant Opdivo, improves event-free survival in NSCLC.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

Bristol Myers Squibb (BMY) closed at $58.58 in the latest trading session, marking a -0.76% move from the prior day.

Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates

Pipeline and regulatory updates from Moderna (MRNA) and Rocket Pharmaceuticals (RCKT) are in focus in the biotech sector.

2seventy bio (TSVT) to Cut Jobs & Expand JW Therapeutics Deal

2seventy bio (TSVT) undertakes a restructuring program and announces plans to reduce 40% of its workforce. The company also plans to expand its collaboration with JW Therapeutics.

The Zacks Analyst Blog Highlights Mastercard, SAP, Texas Instruments, Bristol-Myers Squibb and AT&T

Mastercard, SAP, Texas Instruments, Bristol-Myers Squibb and AT&T are included in this Analyst Blog.

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

Bristol Myers Squibb (BMY) closed at $60.24 in the latest trading session, marking a -0.94% move from the prior day.

Sheraz Mian headshot

Top Analyst Reports for Mastercard, SAP & Texas Instruments

Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), SAP SE (SAP) and Texas Instruments Incorporated (TXN).

Bristol Myers' (BMY) Pulmonary Fibrosis Drug Positive in Phase II

Bristol Myers (BMY) posts encouraging data from a phase II study in progressive pulmonary fibrosis.

Prothena (PRTA) Skyrockets 88.7% in 12 Months: Here's Why

Prothena (PRTA) gains a massive 88.7% in 12 months on pipeline progress with its AD candidates.

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

Bristol Myers Squibb (BMY) closed the most recent trading day at $59.67, moving -1.6% from the previous trading session.

Why Is Axsome (AXSM) Up 8.6% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Exelixis (EXEL) Stock Gains 41.8% So Far in 2023: Here's Why

Exelixis' (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Its efforts to develop additional drugs to expand its portfolio are poised to reap rewards for the company.

Why Is Repligen (RGEN) Up 2.9% Since Last Earnings Report?

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $61.65, marking a -1.17% move from the previous day.

Vertex (VRTX) Down 2.1% Since Last Earnings Report: Can It Rebound?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More

Regulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector.

Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Bristol Myers Squibb (BMY) closed at $62.38, marking a -0.75% move from the previous day.

Apellis Pharmaceuticals, Inc. (APLS) Up 67.8% Since Last Earnings Report: Can It Continue?

Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kinjel Shah headshot

Medicare's First Price Negotiation List Targets Expensive Drugs

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

10 Drugs Selected for Medicare Price Reduction

10 Drugs Selected for Medicare Price Reduction

Mark Vickery headshot

Medicare Drugs Targeted Under Inflation Reduction Act

Last year, these 10 drugs made up $50 billion, about 20%, of Medicare part D costs.